2023
Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon
Teaw S, Gupta A, Williams A, Wilson F, Sumpio B, Sumpio B, Hinchcliff M. Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon. Arthritis Research & Therapy 2023, 25: 10. PMID: 36670487, PMCID: PMC9854186, DOI: 10.1186/s13075-023-02990-3.Peer-Reviewed Original ResearchConceptsRaynaud's condition scoreCochin Hand Function ScaleSSc patientsClinic settingPatient-reported outcome instrumentsResultsNinety-two percentSystemic sclerosis patientsMann-Whitney U testHealthy control participantsCHF scoreSSc durationSSc-RPDigital ulcersCutaneous SScProvocation challengeRaynaud's phenomenonSclerosis patientsClinical trialsOutcome instrumentsOxygen saturationBurden assessmentPatientsCold provocationHemoglobin concentrationDisease severity
2021
Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis.
Feher A, Boutagy NE, Oikonomou EK, Thorn S, Liu YH, Miller EJ, Sinusas AJ, Hinchcliff M. Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis. The Journal Of Rheumatology 2021, 48: 1574-1582. PMID: 34266986, PMCID: PMC10275580, DOI: 10.3899/jrheum.210040.Peer-Reviewed Original ResearchConceptsReduced Myocardial Flow ReserveMyocardial flow reserveRaynaud's phenomenonPrimary Raynaud's phenomenonSecondary Raynaud's phenomenonPatient controlsHealthy participantsFlow reservePositron Emission Tomography/Computed TomographyEmission Tomography/Computed TomographyTomography/Computed TomographyPositron emission tomography/Impaired Myocardial Flow ReserveCoronary microvascular dysfunctionLarge prospective studiesMultivariable logistic regressionEmission tomography/PET/CTSSc-RPMicrovascular dysfunctionClinical predictorsIndependent predictorsSystemic sclerosisPrognostic valueProspective study
2008
Systemic sclerosis/scleroderma: a treatable multisystem disease.
Hinchcliff M, Varga J. Systemic sclerosis/scleroderma: a treatable multisystem disease. American Family Physician 2008, 78: 961-8. PMID: 18953973.Peer-Reviewed Original ResearchConceptsInternal organ involvementSystemic sclerosisOrgan involvementRaynaud's phenomenonEndothelin-1 receptor blockerChronic connective tissue diseaseEnd-organ dysfunctionEnzyme inhibitor therapyHigh-dose corticosteroidsScleroderma renal crisisPulmonary arterial hypertensionPulmonary function testingConnective tissue diseaseDisease-modifying therapiesDistinct clinical subsetInternal organ dysfunctionOrgan-specific manifestationsPhosphodiesterase-5 inhibitorsMiddle-age womenOptimal patient careWidespread microvascular damageRenal crisisArterial hypertensionDigital ulcersLifestyle modification